Insulin resistance increases the occurrence of new cardiovascular events in patients with manifest arterial disease without known diabetes. The SMART study

Cardiovascular Diabetology

Volumn 10, Issue , 2011, Pages

  Verhagen, Sandra N ^a   Wassink, Annemarie M J ^a   van der Graaf, Yolanda ^a   Gorter, Petra M ^a   Visseren, Frank L J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Insulin resistance; Manifest arterial disease; Metabolic syndrome

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT;

ABDOMINAL AORTA ANEURYSM; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HAZARD RATIO; HEART DEATH; HEART INFARCTION; HOMEOSTASIS MODEL OF INSULIN RESISTANCE; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORTALITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROSPECTIVE STUDY; RISK FACTOR; STROKE; SYMPTOM; ANALYSIS OF VARIANCE; MIDDLE AGED; NETHERLANDS; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; TIME;

AGED; ANALYSIS OF VARIANCE; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NETHERLANDS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 81355149219     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-10-100     Document Type: Article

References (42)

1. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, Bonadonna RC, Muggeo M. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population: the Bruneck study. Diabetes Care 2007, 30:318-324. 10.2337/dc06-0919, 17259501.
2. Lakka HM, Lakka TA, Tuomilehto J, Salonen JT. Abdominal obesity is associated with increased risk of acute coronary events in men. Eur Heart J 2002, 23:706-713. 10.1053/euhj.2001.2889, 11977996.
3. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005, 365:1415-1428. 10.1016/S0140-6736(05)66378-7, 15836891.
4. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752. 10.1161/CIRCULATIONAHA.105.169404, 16157765.
5. Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, Saggiani F, Poli M, Perbellini S, Raffaelli A, Cacciatori V, Santi L, Targher G, Bonadonna R, Muggeo M. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002, 25:1135-1141. 10.2337/diacare.25.7.1135, 12087010.
6. Adler AI, Levy JC, Matthews DR, Stratton IM, Hines G, Holman RR. Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67). Diabet Med 2005, 22:306-311. 10.1111/j.1464-5491.2004.01418.x, 15717879.
7. Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care 2002, 25:1177-1184. 10.2337/diacare.25.7.1177, 12087016.
8. Hedblad B, Nilsson P, Engstrom G, Berglund G, Janzon L. Insulin resistance in non-diabetic subjects is associated with increased incidence of myocardial infarction and death. Diabet Med 2002, 19:470-475. 10.1046/j.1464-5491.2002.00719.x, 12060058.
9. Meigs JB, Rutter MK, Sullivan LM, Fox CS, D'Agostino RB, Wilson PW. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care 2007, 30:1219-1225. 10.2337/dc06-2484, 17259468.
10. Resnick HE, Jones K, Ruotolo G, Jain AK, Henderson J, Lu W, Howard BV. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic american indians: the Strong Heart Study. Diabetes Care 2003, 26:861-867. 10.2337/diacare.26.3.861, 12610050.
11. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB, Wilson PW. Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. Diabetes 2005, 54:3252-3257. 10.2337/diabetes.54.11.3252, 16249452.
12. Saely CH, Aczel S, Marte T, Langer P, Hoefle G, Drexel H. The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. J Clin Endocrinol Metab 2005, 90:5698-5703. 10.1210/jc.2005-0799, 16091486.
13. Tenenbaum A, Adler Y, Boyko V, Tenenbaum H, Fisman EZ, Tanne D, Lapidot M, Schwammenthal E, Feinberg MS, Matas Z, Morto M, Behar S. Insulin resistance is associated with increased risk of major cardiovascular events in patients with preexisting coronary artery disease. Am Heart J 2007, 153:559-565. 10.1016/j.ahj.2007.01.008, 17383294.
14. Yanase M, Takatsu F, Tagawa T, Kato T, Arai K, Koyasu M, Horibe H, Nomoto S, Takemoto K, Shimizu S, Watarai M. Insulin resistance and fasting hyperinsulinemia are risk factors for new cardiovascular events in patients with prior coronary artery disease and normal glucose tolerance. Circ J 2004, 68:47-52. 10.1253/circj.68.47, 14695465.
15. Gorter PM, Olijhoek JK, van der Graaf Y, Algra A, Rabelink TJ, Visseren FL. Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Atherosclerosis 2004, 173:363-369.
16. Olijhoek JK, van der Graaf Y, Banga JD, Algra A, Rabelink TJ, Visseren FL. The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 2004, 25:342-348. 10.1016/j.ehj.2003.12.007, 14984924.
17. Martens FM, Visseren FL. The operative risk factors in the metabolic syndrome: is it lipids and high BP or are there direct vascular effects of insulin resistance and obesity. Curr Diab Rep 2007, 7:74-81. 10.1007/s11892-007-0013-7, 17254521.
18. Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000, 152:897-907. 10.1093/aje/152.10.897, 11092431.
19. Scuteri A, Najjar SS, Muller DC, Andres R, Hougaku H, Metter EJ, Lakatta EG. Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness. J Am Coll Cardiol 2004, 43:1388-1395. 10.1016/j.jacc.2003.10.061, 15093872.
20. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y. Second manifestations of ARTerial disease (SMART) study: rationale and design. Eur J Epidemiol 1999, 15:773-781. 10.1023/A:1007621514757, 10608355.
21. Wassink AM, van der Graaf Y, van Haeften TW, Spiering W, Soedamah-Muthu SS, Visseren FL. Waist circumference and metabolic risk factors have separate and additive effects on the risk of future Type 2 diabetes in patients with vascular diseases. A cohort study. Diabet Med 2011, 28:932-940. 10.1111/j.1464-5491.2011.03318.x, 21749443.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419. 10.1007/BF00280883, 3899825.
23. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000, 23:57-63. 10.2337/diacare.23.1.57, 10857969.
24. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care 1997, 20:1087-1092. 10.2337/diacare.20.7.1087, 9203442.
25. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008, 294:E15-E26.
26. Caccamo G, Bonura F, Bonura F, Vitale G, Novo G, Evola S, Evola G, Grisanti MR, Novo S. Insulin resistance and acute coronary syndrome. Atherosclerosis 2010, 211:672-675. 10.1016/j.atherosclerosis.2010.03.033, 20466373.
27. Spencer M, Unal R, Zhu B, Rasouli N, McGehee RE, Peterson CA, Kern PA. Adipose Tissue Extracellular Matrix and Vascular Abnormalities in Obesity and Insulin Resistance. J Clin Endocrinol Metab 2011,
28. Pasarica M, Sereda OR, Redman LM, Albarado DC, Hymel DT, Roan LE, Rood JC, Burk DH, Smith SR. Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes 2009, 58:718-725. 2646071, 19074987.
29. van de Woestijne AP, Monajemi H, Kalkhoven E, Visseren FL. Adipose tissue dysfunction and hypertriglyceridemia: mechanisms and management. Obes Rev 2011, 12:829-840. 10.1111/j.1467-789X.2011.00900.x, 21749607.
30. Khan AM, Cheng S, Magnusson M, Larson MG, Newton-Cheh C, McCabe EL, Coviello AD, Florez JC, Fox CS, Levy D, Robins SJ, Arora P, Bhasin S, Lam CS, Vasan RS, Melander O, Wang TJ. Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metab 2011, 96:3242-3249. 10.1210/jc.2011-1182, 21849523.
31. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J, . PROactive investigators Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289. 10.1016/S0140-6736(05)67528-9, 16214598, PROactive investigators.
32. Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009, 360:2503-2515. 2863990, 19502645.
33. Shin JY, Lee HR, Lee DC. Increased arterial stiffness in healthy subjects with high-normal glucose levels and in subjects with pre-diabetes. Cardiovasc Diabetol 2011, 10:30. 10.1186/1475-2840-10-30, 3098149, 21492487.
34. Gomez-Marcos MA, Recio-Rodriguez JI, Patino-Alonso MC, gudo-Conde C, Gomez-Sanchez L, Rodriguez-Sanchez E, Martin-Cantera C, Garcia-Ortiz L. Relationship between intima-media thickness of the common carotid artery and arterial stiffness in subjects with and without type 2 diabetes: a case-series report. Cardiovasc Diabetol 2011, 10:3. 10.1186/1475-2840-10-3, 3034668, 21226947.
35. Wheatcroft SB, Williams IL, Shah AM, Kearney MT. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med 2003, 20:255-268. 10.1046/j.1464-5491.2003.00869.x, 12675638.
36. Wassink AM, van der Graaf Y, Olijhoek JK, Visseren FL. Metabolic syndrome and the risk of new vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 2008, 29:213-223.
37. Tenenbaum A, Fisman EZ. "The metabolic syndrome... is dead": these reports are an exaggeration. Cardiovasc Diabetol 2011, 10:11. 10.1186/1475-2840-10-11, 3036609, 21269524.
38. Faber DR, de Groot PG, Visseren FL. Role of adipose tissue in haemostasis, coagulation and fibrinolysis. Obes Rev 2009,
39. Trovati M, Anfossi G, Cavalot F, Massucco P, Mularoni E, Emanuelli G. Insulin directly reduces platelet sensitivity to aggregating agents. Studies in vitro and in vivo. Diabetes 1988, 37:780-786. 10.2337/diabetes.37.6.780, 2838353.
40. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006, 113:1888-1904. 10.1161/CIRCULATIONAHA.105.563213, 16618833.
41. Goff DC, D'Agostino RB, Haffner SM, Otvos JD. Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study. Metabolism 2005, 54:264-270. 10.1016/j.metabol.2004.09.002, 15690322.
42. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979, 237:E214-E223.